Viral infections in patients with hematological malignancies.
Viral infections are important causes of morbidity and mortality for patients with a hematological malignancy. However, the true incidence and consequences of viral infections for these patients who undergo conventional nontransplant therapy are poorly defined. The difference in incidence and outcome of viral infections among patient groups is wide, but dependent upon the intensity and duration of T-cell-mediated immune suppression. Infections caused by cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV), respiratory syncytial virus (RSV), parainfluenza viruses and influenza viruses have been intensely studied, yet newly recognized aspects of these viral infections including late CMV infection; the emergence of new viral pathogens (human herpesvirus-6, BK virus, adenovirus, and human metapneumovirus); the development of molecular diagnostic techniques, and the potential of new agents for viral prophylaxis (maribavir), or preemptive therapy (valganciclovir) form the basis of this review. Well-designed prospective studies are needed to better clarify the spectrum of these viral infections and develop effective prevention and treatment strategies. Yet the increased use of agents like alemtuzumab that induce profound T-cell depletion demands that we develop a better understanding of viral infections that occur in patients with hematological malignancy who receive nontransplant therapy.
Wade
James C
JC
Medical College of Wisconsin, 9200 W. WI Ave., FEC 3963A, Milwaukee WI 53226, USA. jwade@mcw.edu
D000970:Antineoplastic Agents / Q000009:adverse effects; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D006801:Humans; D011292:Premedication / Q000379:methods; D014777:Virus Diseases / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*
D000970:Antineoplastic Agents